HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Roundup: P&G Leadership, Unilever Sale, Ad Claims

This article was originally published in The Tan Sheet

Executive Summary

Patterson Medical adds Performance Health; EarlySense targets consumer expansion; faster capsule filler available; and more news in brief.

You may also be interested in...



Cough/Cold, Analgesic Patch Sales Ease Pain Of Private Label Growth In OTCs

Topical analgesic sales grew double digits in 2017 on innovation and adhesive patch launches, helping drive 2.1% growth of US manufacturers' OTC drug sales in 2017 to $21.2bn, Kline & Co. independent consultant Laura Mahecha says. But private label continues to outpace branded product sales growth.

Cough/Cold, Analgesic Patch Sales Ease Pain Of Private Label Growth In OTCs

Topical analgesic sales grew double digits in 2017 on innovation and adhesive patch launches, helping drive 2.1% growth of US manufacturers' OTC drug sales in 2017 to $21.2bn, Kline & Co. independent consultant Laura Mahecha says. But private label continues to outpace branded product sales growth.

UK Short-Circuits OTC Device Pain Relief Claims For Diabetics, Arthritics

Ad claims for Actegy's Revitive Circulation Booster device did not rely on clinical evidence that tested the actual product in the way consumers were advised to use it, UK advertising regulator says. Actegy maintained benefits from the device's TENS technology are similar to the effects of NMES technology used in studies it offered as evidence.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS108921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel